Prothena Corporation plc (PRTA)

$56.71

-4.50 (-7.35%)
Rating:
Recommendation:
Buy
Symbol PRTA
Price $56.71
Beta 0.481
Volume Avg. 0.83M
Market Cap 2.743B
Shares () -
52 Week Range 21.06-65.35
1y Target Est -
DCF Unlevered PRTA DCF ->
DCF Levered PRTA LDCF ->
ROE -36.46% Strong Sell
ROA -28.22% Sell
Operating Margin -
Debt / Equity 37.02% Neutral
P/E 38.58 Strong Buy
P/B 6.58 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PRTA news


Dr. Gene Kinney
Healthcare
Biotechnology
NASDAQ Global Select

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.